This study investigates the use of an investigational medication in combination with paclitaxel for patients with advanced cancers. These cancers include ovarian, breast, non-small cell lung, melanoma, gastric, esophageal, and others that are metastatic, cannot be removed by surgery, or have come back after treatment. The purpose is to understand how the investigational medication works with paclitaxel in these conditions.

Participants in the study will receive a combination of the investigational medication and paclitaxel. The study will monitor the effects and safety of this treatment. Paclitaxel is a chemotherapy drug used to treat various types of cancer. This study aims to find out the best dose and to see how well patients respond to the treatment.

• Who can participate: Adults with advanced ovarian, breast, non-small cell lung, melanoma, gastric, esophageal, or other cancers that are metastatic, unresectable, or recurrent may participate. Participants must have measurable disease and a life expectancy of at least 3 months, and they must agree to use contraception if of childbearing potential.
• Study details: Participants will take the investigational medication in combination with paclitaxel. A placebo, which is an inactive substance that looks like the investigational medication but does not contain any medicine, is not used in this study. Participants must be able to swallow capsules daily.